These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36629855)

  • 1. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
    Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
    MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing developability early in the discovery process for novel biologics.
    Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
    MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
    Thorsteinson N; Comeau SR; Kumar S
    Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
    Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
    MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
    Makowski EK; Wu L; Gupta P; Tessier PM
    MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developability assessment for monoclonal antibody drug candidates: a case study.
    Garripelli VK; Wu Z; Gupta S
    Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
    Liu Y; Caffry I; Wu J; Geng SB; Jain T; Sun T; Reid F; Cao Y; Estep P; Yu Y; Vásquez M; Tessier PM; Xu Y
    MAbs; 2014; 6(2):483-92. PubMed ID: 24492294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
    Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
    Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
    Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
    Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
    Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
    Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
    Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
    MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
    Dyson MR; Masters E; Pazeraitis D; Perera RL; Syrjanen JL; Surade S; Thorsteinson N; Parthiban K; Jones PC; Sattar M; Wozniak-Knopp G; Rueker F; Leah R; McCafferty J
    MAbs; 2020; 12(1):1829335. PubMed ID: 33103593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
    Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
    Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.